More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$517.59B
EPS
3.54
P/E ratio
78.1
Price to sales
7.59
Dividend yield
2.486%
Beta
0.201107
Previous close
$294.55
Today's open
$291.50
Day's range
$291 - $294.06
52 week range
$190.75 - $302.93
show more
CEO
ROBERT A. MICHAEL
Employees
57000
Headquarters
North Chicago, IL
Exchange
New York Stock Exchange
Shares outstanding
1.77B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life
Four blue-chip dividend payers, including one that sends checks monthly, offer a way to keep the shares and still get paid.
24/7 Wall Street • 2 hours ago

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research • Nov 17, 2026

How Did AbbVie's Neuroscience Franchise Perform in Q3?
ABBV's neuroscience franchise delivers 19.5% operational sales growth in Q3, prompting the company to raise its 2026 segment sales outlook to $13 billion.
Zacks Investment Research • 21 hours ago

Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) grounds countless retirement portfolios. SCHD screens for durable dividend payers, holds $112.3 billion in net assets and pays a trailing yield near 2.94%.
24/7 Wall Street • Nov 17, 2026

Invest $200,000 in These 5 Dividend Stocks to Fund Your Retirement Income
Retirement changes the job a portfolio has to do. Once the paychecks stop, every bill depends on what the portfolio produces, and selling shares in a down market to cover expenses locks in losses.
24/7 Wall Street • a day ago

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.
The Motley Fool • Nov 14, 2026

How Did AbbVie's Immunology Franchise Fare in Q3?
ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.
Zacks Investment Research • Nov 12, 2026

3 Pharmaceutical Stocks That Offer Safety and Growth
Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.
MarketBeat • Nov 12, 2026

ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
AbbVie's strong immunology and neuroscience growth offset Humira erosion and persistent aesthetics and oncology challenges.
Zacks Investment Research • Nov 11, 2026

Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
– HARMONY IN DIVERSITY is the first study of combined neurotoxin and filler treatment in adults on glucagon-like peptide-1 (GLP-1) medications. In this Phase 4 cohort, participants reported statistically significant improvements in satisfaction with facial appearance and skin quality following a treatment regimen that also included skincare – Interim results from HALO, a Phase 4 study of hyaluronic acid (HA) injectables in adults on GLP-1 medications, showed high patient satisfaction, with 95.7% of participants satisfied or very satisfied that they still looked like themselves – The findings are part of a broad Allergan Aesthetics scientific program at ASDS 2026, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation and skin quality IRVINE, Calif.
PRNewsWire • Nov 8, 2026

¹ Disclosures

Open an M1 investment account to buy and sell AbbVie Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.